.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,169,791

« Back to Dashboard
Patent 7,169,791 protects TASIGNA and is included in one NDA. There has been one Paragraph IV challenge on Tasigna.

This patent has fifty-five patent family members in thirty countries.

Summary for Patent: 7,169,791

Title:Inhibitors of tyrosine kinases
Abstract:The invention relates to compounds of formula ##STR00001## wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
Inventor(s): Breitenstein; Werner (Basel, CH), Furet; Pascal (Thann, FR), Jacob; Sandra (Rantzwiller, FR), Manley; Paul William (Arlesheim, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:10/520,359
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 8th percentile
Forward Citations: 4th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis
TASIGNA
nilotinib hydrochloride monohydrate
CAPSULE;ORAL022068-002Jun 17, 2010RXNo7,169,791► subscribeYY A METHOD FOR THE TREATMENT OF LEUKEMIAS
Novartis
TASIGNA
nilotinib hydrochloride monohydrate
CAPSULE;ORAL022068-001Oct 29, 2007RXYes7,169,791► subscribeYY A METHOD FOR THE TREATMENT OF LEUKEMIAS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,169,791

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0215676.8Jul 05, 2002
United Kingdom0229893.3Dec 20, 2002
PCT Information
PCT FiledJuly 04, 2003PCT Application Number:PCT/EP03/07198
PCT Publication Date:January 15, 2004PCT Publication Number: WO20/04/005281

Non-Orange Book Patents for Patent: 7,169,791

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,956,053Inhibitors of tyrosine kinases► subscribe
7,569,566Inhibitors of tyrosine kinases► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,169,791

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan200403060► subscribe
Slovenia1532138► subscribe
Russian Federation2445309► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc